Search research articles
Contact Us
Filters
Showing results (51-60 of 59) with videos related to
Page
of 6
Sort By:
You have reached the last page of results.
This site can display upto 59 results.
Antimicrobial Agents and Chemotherapy
|
August 26, 2004
Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine
D J Tenney, S M Levine, R E Rose, et al.
Antimicrobial Agents and Chemotherapy
|
December 21, 2006
Two-year assessment of entecavir resistance in Lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present
Daniel J Tenney, Ronald E Rose, Carl J Baldick, et al.
Plos One
|
February 15, 2018
Safety and efficacy of anti-PD-L1 therapy in the woodchuck model of HBV infection
Scott Balsitis, Volodymyr Gali, Pamela J Mason, et al.
Plos Pathogens
|
September 15, 2010
A novel small molecule inhibitor of hepatitis C virus entry
Carl J Baldick, Michael J Wichroski, Annapurna Pendri, et al.
Plos One
|
August 11, 2012
High-throughput screening and rapid inhibitor triage using an infectious chimeric Hepatitis C virus
Michael J Wichroski, Jie Fang, Betsy J Eggers, et al.
Molecular Imaging and Biology
|
December 20, 2023
Development, Characterization, and Radiation Dosimetry Studies of <sup>18</sup>F-BMS-986229, a <sup>18</sup>F-Labeled PD-L1 Macrocyclic Peptide PET Tracer
Joonyoung Kim, David J Donnelly, Tritin Tran, et al.
Hepatology International
|
August 12, 2009
Two cases of development of entecavir resistance during entecavir treatment for nucleoside-naive chronic hepatitis B
Haruhiko Kobashi, Shin-Ichi Fujioka, Mitsuhiko Kawaguchi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 26, 2022
Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915)
Jeffrey S Weber, Dirk Schadendorf, Michele Del Vecchio, et al.
Cancer Cell
|
August 30, 2024
Combination anti-PD-1 and anti-CTLA-4 therapy generates waves of clonal responses that include progenitor-exhausted CD8<sup>+</sup> T cells
Kevin Wang, Paulina Coutifaris, David Brocks, et al.
Page
of 6
Search research articles
Search
Showing results (51-60 of 59) with videos related to
Sort By:
Page
of 6
You have reached the last page of results.
This site can display upto 59 results.
Antimicrobial Agents and Chemotherapy
|
August 26, 2004
Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine
D J Tenney, S M Levine, R E Rose, et al.
Antimicrobial Agents and Chemotherapy
|
December 21, 2006
Two-year assessment of entecavir resistance in Lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present
Daniel J Tenney, Ronald E Rose, Carl J Baldick, et al.
Plos One
|
February 15, 2018
Safety and efficacy of anti-PD-L1 therapy in the woodchuck model of HBV infection
Scott Balsitis, Volodymyr Gali, Pamela J Mason, et al.
Plos Pathogens
|
September 15, 2010
A novel small molecule inhibitor of hepatitis C virus entry
Carl J Baldick, Michael J Wichroski, Annapurna Pendri, et al.
Plos One
|
August 11, 2012
High-throughput screening and rapid inhibitor triage using an infectious chimeric Hepatitis C virus
Michael J Wichroski, Jie Fang, Betsy J Eggers, et al.
Molecular Imaging and Biology
|
December 20, 2023
Development, Characterization, and Radiation Dosimetry Studies of <sup>18</sup>F-BMS-986229, a <sup>18</sup>F-Labeled PD-L1 Macrocyclic Peptide PET Tracer
Joonyoung Kim, David J Donnelly, Tritin Tran, et al.
Hepatology International
|
August 12, 2009
Two cases of development of entecavir resistance during entecavir treatment for nucleoside-naive chronic hepatitis B
Haruhiko Kobashi, Shin-Ichi Fujioka, Mitsuhiko Kawaguchi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 26, 2022
Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915)
Jeffrey S Weber, Dirk Schadendorf, Michele Del Vecchio, et al.
Cancer Cell
|
August 30, 2024
Combination anti-PD-1 and anti-CTLA-4 therapy generates waves of clonal responses that include progenitor-exhausted CD8<sup>+</sup> T cells
Kevin Wang, Paulina Coutifaris, David Brocks, et al.
Page
of 6